MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements ...

Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

This week's dividend activity included increased payouts from Bestbuy (BBY) and JD.com (NASDAQ:JD) as well as declarations ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...